FY2026 EPS Estimates for AptarGroup Raised by Zacks Research
Zacks Research has increased its FY2026 EPS estimate for AptarGroup to $5.53 from $5.46, nearing the consensus of $5.54. The research firm also provided elevated EPS forecasts for FY2027 ($5.91) and FY2028 ($6.65). This positive revision follows AptarGroup's strong quarterly performance, where it surpassed analyst estimates with an EPS of $1.52 and reported revenue of $1.02 billion, a 6% year-over-year increase.
Law firm investigates AptarGroup directors for possible fiduciary breaches affecting shareholders
Purcell & Lefkowitz LLP is investigating AptarGroup, Inc.'s directors for potential breaches of fiduciary duty, aiming to protect shareholders' rights and determine if any misconduct occurred. This investigation could affect AptarGroup's governance and shareholder confidence. The article also provides a market snapshot for the Consumer Staples sector, noting recent stock performance for companies like Conagra Brands Inc, Adecoagro SA, and Kimberly Clark Corp.
How Aptargroup Inc. (ATR) Affects Rotational Strategy Timing
This article analyzes Aptargroup Inc. (NYSE: ATR) and its impact on rotational strategy timing, utilizing AI models to generate three distinct trading strategies: Position Trading, Momentum Breakout, and Risk Hedging. It provides key findings including prevailing positive sentiment, potential for upside, and detailed signal analysis across near-term, mid-term, and long-term horizons, with specific entry, target, and stop loss levels for each strategy.
Be Sure To Check Out AptarGroup, Inc. (NYSE:ATR) Before It Goes Ex-Dividend
AptarGroup, Inc. (NYSE:ATR) is set to trade ex-dividend in the next four days, with a dividend payment of US$0.50 per share. The company has a trailing yield of 1.4% and demonstrates strong dividend sustainability, paying out 46% of its profit and 42% of its free cash flow. AptarGroup has also shown consistent earnings per share growth of 4.9% annually over the last five years and a 5.2% average annual dividend increase over the past decade.
Form 4 AptarGroup Inc: George L. Fotiades (Director) For: 5 November
This article reports on a Form 4 filing for AptarGroup Inc., detailing a transaction by director George L. Fotiades on November 5. The filing indicates insider trading activity for the company, which is of interest to investors tracking corporate governance and stock movements.
Form 4 AptarGroup Inc: George L. Fotiades (Director) For: 5 November By Investing.com
This article reports on a Form 4 filing for AptarGroup Inc, detailing a transaction by Director George L. Fotiades on November 5th. Form 4 filings are used to disclose changes in beneficial ownership of securities by a company's insiders. The brief news item indicates a specific transaction for AptarGroup Inc.
AptarGroup Inc stock hits 52-week high at 146.92 USD By Investing.com
AptarGroup Inc (ATR) has reached a new 52-week high of $146.92, reflecting significant growth driven by strong market demand and strategic business initiatives. Despite appearing overvalued according to InvestingPro analysis, the company reported stronger-than-expected Q3 2026 results and received an increased price target from BofA Securities. Investors are monitoring its performance as it continues to innovate and expand its market presence.
AptarGroup Inc stock hits 52-week high at 146.92 USD By Investing.com
AptarGroup Inc. (ATR) stock recently hit a 52-week high of $146.92, driven by strong market demand and strategic business initiatives, with a 1-year change of 26.49%. Despite appearing overvalued according to InvestingPro analysis, the company reported stronger-than-expected Q3 2026 results, with adjusted EPS of $1.52 and revenue of $1.02 billion, beating Wall Street estimates. BofA Securities raised its price target to $155, maintaining a Buy rating, citing growth in Pharma core sales.
$274K in AptarGroup (ATR) shares is slated for sale by officer Marc Prieur.
AptarGroup officer Marc Prieur plans to sell 2,000 common shares of the company, valued at $274,000, around November 2, 2026, through UBS Switzerland AG. The sale involves Restricted Stock Units (RSUs) and Performance Stock Units (PSUs). Additionally, the filing reports a previous sale of 3,500 common shares for over $476,000 on June 9, 2026.
AptarGroup 3Q 2026: Revenue $1.02B, Net income $32.6M, EPS $0.51— 10-Q Summary
AptarGroup reported its third-quarter 2026 financial results, with revenue increasing 6% year-over-year to $1.02 billion. Despite the revenue growth, net income and diluted EPS saw significant declines of 74.5% and 73.4%, respectively. The company also provided fourth-quarter adjusted EPS guidance ranging from $1.39 to $1.47.
Aptar Earnings: Headline Result Masks Excellent Underlying Margin Improvement in Pharma
Aptar's core sales increased by 5% year-on-year, though adjusted EBITDA margin saw a 190 basis point decline to 21.3%. Despite overall margin compression, the pharma segment's EBITDA margin declined by a relatively smaller 80 basis points, suggesting underlying strength in that area. Following the announcement, Aptar's shares rose by 5%.
AptarGroup Edges Past Q3 2026 Estimates, Posts $1.52 EPS, Revenue Up 6%
AptarGroup, Inc. (NYSE:ATR) reported strong Q3 2026 results, with adjusted earnings of $1.52 per share, surpassing Wall Street's estimate of $1.49. Revenue increased by 6.0% year-over-year to $1.02 billion, driven by core sales growth and robust performance in its Pharma division. The positive earnings beat and underlying momentum led to a 2.7% rise in the company's shares.
AptarGroup Q3 2026 Earnings Call Transcript
AptarGroup (NYSE: ATR) reported 5% core sales growth across all segments and adjusted EPS at the high end of guidance for Q3 2026, despite challenges from emergency medicine destocking. The company emphasized strategic opportunities in pharma, including innovations in ophthalmic and nasal drug delivery, and a robust pipeline. While Beauty and Closures segments showed strong sales growth, profitability in Beauty, especially in North America, remains a key area for improvement.
Earnings Flash (ATR) AptarGroup, Inc. Posts Q3 Adjusted EPS $1.52 per Share, Vs. FactSet Est of $1.47
AptarGroup, Inc. (ATR) reported adjusted earnings per share of $1.52 for the third quarter, surpassing the FactSet estimate of $1.47. This indicates stronger-than-expected financial performance for the company during the quarter.
Aptar Reports Third Quarter 2026 Results
AptarGroup, Inc. (NYSE:ATR) reported its third quarter 2026 results, showing a 6% increase in reported sales and a 5% increase in core sales. The company achieved adjusted earnings per share of $1.52 and an adjusted EBITDA margin of 23.3%. Aptar also returned $61 million to shareholders in the quarter through share repurchases and dividends and subsequently increased its quarterly cash dividend to $0.50.
AptarGroup Sales Rise 6%; Adjusted EPS Reaches $1.52
AptarGroup reported a 6% year-over-year increase in third-quarter 2026 sales, reaching $1.02 billion, while adjusted diluted EPS was $1.52. The company's reported diluted EPS was $0.51, impacted by a $60.4 million after-tax charge due to the deconsolidation of its Russian subsidiary. AptarGroup highlighted strong demand in various sectors, including pharma, beauty, and closures, despite challenges in North American beauty operations and emergency medicine destocking.
Aptar Reports Third Quarter 2026 Results
AptarGroup, Inc. reported a 6% increase in reported sales and a 5% increase in core sales for the third quarter of 2026, reaching $1.02 billion. Despite a loss on deconsolidation of its Russian subsidiary impacting reported net income and EPS, adjusted earnings per share were $1.52, at the higher end of guidance. The company saw broad-based revenue growth across all segments, with Pharma delivering impressive growth in key therapeutic areas and Closures achieving double-digit core sales growth.
Aptar Increases Quarterly Dividend to $0.50 Per Share
AptarGroup, Inc. (NYSE: ATR) announced that its Board of Directors declared a quarterly cash dividend of $0.50 per share, an increase of approximately 4% from the previous dividend of $0.48 per share. This increase puts Aptar on track for its 33rd consecutive year of annually increasing dividends, reflecting the company's confidence in future growth and commitment to creating long-term shareholder value. The payment date is December 3, 2026, for stockholders of record as of November 12, 2026.
Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection
Stevanato Group and Aptar Pharma have partnered to accelerate the selection of pre-filled syringe systems for biotech and pharmaceutical companies. This collaboration involves system-level testing of Stevanato Group’s glass syringes with Aptar Pharma’s elastomer components to provide crucial data earlier in the development process, especially for sensitive biologics and injectable therapies. The initiative aims to help drug manufacturers identify potential challenges sooner and make more informed packaging decisions.
Aptar Pharma and Stevanato Group Collaborate to Help Accelerate Pre-Filled Syringe System Selection
Aptar Pharma and Stevanato Group have announced a collaboration to provide system-level data for pre-filled syringe configurations, aiming to accelerate the evaluation process for biotech and pharmaceutical companies. This joint effort combines Stevanato Group's glass syringes with Aptar Pharma's elastomer components to assess assembled systems, particularly for sensitive biologics and injectable therapies. The goal is to offer drug manufacturers earlier insights into component interactions and system performance, supporting more informed development decisions and risk evaluation.
Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection
Stevanato Group and Aptar Pharma have partnered to accelerate the selection of pre-filled syringe systems, particularly for sensitive biologics. This collaboration involves system-level testing of Stevanato Group’s glass syringes with Aptar Pharma’s elastomer components to provide crucial data earlier in the development process, aiding pharmaceutical companies in making informed packaging decisions and meeting USP <382> requirements. The initiative aims to enhance confidence in how packaging components perform together as complete systems, addressing the increasing complexity of injectable therapies.
Aptar Pharma and Stevanato Group Collaborate to Help Accelerate Pre-Filled Syringe System Selection
Aptar Pharma and Stevanato Group have announced a collaboration to provide system-level data that supports earlier evaluation of pre-filled syringe configurations for biotech and pharmaceutical companies. This joint effort will focus on sensitive biologics and other injectable therapies, helping drug manufacturers make more informed decisions and identify potential technical challenges sooner in the development process. The initiative builds on Aptar Pharma's integrated system-level framework launched in July 2026, combining their expertise in elastomeric components with Stevanato Group's knowledge in pre-fillable syringe systems.
Aptar Pharma Acquires Pulmotree to Expand Pulmonary Drug Delivery Technology
Aptar Pharma, a division of AptarGroup Inc., has acquired Pulmotree, a Munich-based life sciences company specializing in pulmonary drug delivery systems. This acquisition follows a two-year collaboration and aims to expand Aptar Pharma's respiratory technology portfolio and accelerate the development and commercialization of Pulmotree's Kolibri Non-Propellant Liquid Inhaler platform. The Kolibri system uses a breath-triggered vibrating mesh to deliver medications directly to the lungs, supporting the administration of complex therapeutic molecules.
Aptar taps packaging executive to run pharma business
AptarGroup has appointed Virginie Maes to lead its pharmaceutical business. This move sees a packaging executive taking the helm of a key division for the company. The announcement was made on October 26, 2026.
AptarGroup, Inc. Estimates – NYSE:ATR
This article provides an overview of AptarGroup, Inc. (NYSE: ATR) financials and estimates available on TradingView. It directs users to explore reported financial data and analyst estimates across various financial statements and valuation metrics. The content emphasizes comparing actual results with average, high, and low estimates and visualizing trends over time.
AptarGroup, Inc. (ATR) Interactive Stock Chart - Yahoo Finance
This Yahoo Finance page provides an interactive stock chart and financial information for AptarGroup, Inc. (ATR). It displays real-time stock prices, after-hours trading, and a schedule for the upcoming Q3 2026 earnings call. The page also includes recent news articles related to AptarGroup, covering collaborations, executive appointments, earnings previews, and stock performance analysis.
Earnings Preview: AptarGroup (ATR) Q3 Earnings Expected to Decline
AptarGroup (ATR) is projected to report a year-over-year decline in Q3 earnings, despite an expected increase in revenues. The company's earnings per share are estimated to be $1.46, a 9.9% decrease, with revenues rising 1.6% to $976.17 million. With a Zacks Earnings ESP of 0% and a Zacks Rank #3, it is difficult to conclusively predict if AptarGroup will beat the consensus EPS estimate.
Aptar Taps Pharma Packaging Veteran Virginie Maes as President of its Pharma Business
AptarGroup, Inc. (NYSE: ATR) announced the appointment of Virginie Maes as President of Aptar Pharma, effective January 1, 2027. Maes joins Aptar from Amcor, bringing extensive global experience in pharmaceutical and medical packaging, growth, and operational performance. Gaël Touya, President and Chief Executive Officer of Aptar, expressed confidence in Maes's ability to lead and grow Aptar's Pharma business.
AptarGroup names Virginie Maes as president of its pharma unit
AptarGroup, Inc. has announced the appointment of Virginie Maes as president of Aptar Pharma, effective January 1, 2027. Maes brings extensive global experience from Amcor, where she led the global Flexibles Pharma and Medical packaging business, and previously held roles at McKinsey & Company, Terra Firma Capital Partners, and Morgan Stanley. Gael Touya, president and CEO of Aptar, expressed confidence in Maes's ability to lead and grow the Pharma business, with Maes highlighting the opportunity to integrate technologies and services across the value chain.
AptarGroup names Virginie Maes president of pharma unit
AptarGroup Inc. announced the appointment of Virginie Maes as President of Aptar Pharma, effective January 1, 2027. Maes brings extensive global experience from Amcor, where she led the global Flexibles Pharma and Medical packaging business, and previously worked at McKinsey & Company, Terra Firma Capital Partners, and Morgan Stanley. Aptar's CEO Gael Touya highlighted Maes's strong customer focus and proven ability to lead and grow complex businesses.
Aptar Taps Pharma Packaging Veteran Virginie Maes as President of its Pharma Business
AptarGroup, Inc. announced the appointment of Virginie Maes as President of Aptar Pharma, effective January 1, 2027. Maes joins Aptar from Amcor, where she led its global flexible pharma and medical packaging business, bringing extensive experience in customer relationships, growth, and operational performance. Gael Touya, President and Chief Executive Officer of Aptar, expressed confidence in Maes's ability to lead and grow Aptar's Pharma business, emphasizing a continued focus on customer partnerships and solving complex challenges.
Aptar Taps Pharma Packaging Veteran Virginie Maes as President of its Pharma Business
AptarGroup, Inc. has announced the appointment of Virginie Maes as President of Aptar Pharma, effective January 1, 2027. Maes brings extensive global experience from Amcor, where she led the Flexibles Pharma and Medical packaging business, and will focus on strengthening customer relationships and driving growth in Aptar's Pharma division. Gael Touya, President and CEO of Aptar, expressed confidence in Maes's ability to lead the business forward, emphasizing continued partnership with customers to solve complex challenges and create value.
UBS starts coverage of AptarGroup stock with USD 135.00 target
UBS has initiated coverage of AptarGroup (NYSE: ATR) stock with a "Hold" rating and a price target of USD 135.00, which is 7.78% above its current NYSE price. The company is set to report its third-quarter earnings on October 29, 2026, with analysts expecting adjusted earnings of USD 1.47 per share and revenue of USD 980.83 million. AptarGroup, with a market capitalization of USD 7.96 billion, operates in pharmaceutical delivery, beauty and home dispensing, and food and beverage closures.
AptarGroup, Inc. (ATR) Stock Forecasts
AptarGroup, Inc. (ATR) is a leading global supplier of dispensing systems for consumer goods and pharmaceuticals, with nearly half its sales from Europe. A recent Morningstar analyst report, dated October 15, 2026, notes that despite destocking in emergency medicines, Aptar's core business remains robust. The report highlights the company's current price of $124.63 and offers an in-depth analysis for premium subscribers.
AptarGroup, Inc. (ATR) Stock Price & News
AptarGroup, Inc. (ATR) is currently trading at US$124.51, showing a slight increase of 0.20%. The company has a market capitalization of US$8.57 billion and a 52-week trading range of US$103.23 to US$146.91. Recent news includes UBS initiating coverage with a Neutral rating and a $135 price target, as well as an insider selling shares worth over $1.3 million.
Aptar Pharma wins CE marking for LuerVax intranasal vaccine device
Aptar Pharma has received CE marking for its LuerVax intranasal delivery device and accompanying Spray Divider under EU Medical Device Regulation. This certification allows the products, designed for vaccine administration by healthcare professionals, to be used in Europe, strengthening Aptar Pharma's support for global vaccine developers. The company also offers regulatory, industrialization, and manufacturing services to aid in the development and commercialization of vaccine programs.
Despite Emergency Medicines Destocking, Aptar's Underlying Business Remains Healthy
Aptar, a global leader in dispensing technologies, is experiencing destocking of emergency medicines, which has impacted its recent earnings. Despite this, the company's core business remains healthy, driven by its focus on higher-margin healthcare products. Aptar operates in Aptar Pharma, Aptar Beauty, and Aptar Closures segments, with healthcare now contributing approximately two-thirds of its operating profits.
AptarGroup, Inc. (ATR) stock price, news, quote and history
This article provides a comprehensive overview of AptarGroup, Inc. (ATR), including its current stock price, historical data, and key financial metrics. It details the company's business segments in drug delivery and consumer product dispensing, as well as its performance against the S&P 500 and analyst ratings.
Aptar Announces CE Marking for LuerVax® and Accompanying Spray Divider, Strengthening Support for Vaccine Developers
Aptar Pharma has announced that its LuerVax® intranasal delivery device and accompanying Spray Divider have received CE marking under the EU Medical Device Regulation. This milestone signifies compliance with European safety and performance requirements, expanding Aptar Pharma's support for vaccine developers. The CE marking enables customers to use a validated intranasal delivery platform from clinical studies through commercialization, facilitating the development of innovative intranasal vaccine products.
Aptar Announces CE marking for LuerVax® and Accompanying Spray Divider, Strengthening Support for Vaccine Developers
Aptar Pharma has announced that its LuerVax® intranasal delivery device and accompanying Spray Divider have received CE marking under the EU Medical Device Regulation. This milestone signifies that the products meet European safety and performance requirements for medical devices and expands Aptar Pharma's ability to support vaccine developers globally. The LuerVax® platform offers a compliant solution for intranasal vaccine development from clinical studies through commercialization, providing flexibility and regulatory support to customers.
Aptar Pharma receives CE mark for intranasal vaccine device
AptarGroup Inc. (NYSE:ATR) announced that its Aptar Pharma LuerVax intranasal delivery device and accompanying Spray Divider have received CE marking under the EU Medical Device Regulation. This certification indicates the products meet European safety and performance requirements for medical devices, allowing them to be used by healthcare professionals for vaccine administration. The LuerVax device is designed to support vaccine development from early clinical studies through commercialization.
Aptar Pharma receives CE mark for intranasal vaccine device By Investing.com
Aptar Pharma has announced that its LuerVax intranasal delivery device and accompanying Spray Divider have received CE marking under the EU Medical Device Regulation. This certification indicates that the products meet European safety and performance requirements for medical devices. The LuerVax device is designed for vaccine administration by healthcare professionals, supporting vaccine development from clinical studies through commercialization.
How Aptargroup Inc. (ATR) Affects Rotational Strategy Timing
This article analyzes Aptargroup Inc. (ATR) with a focus on its impact on rotational strategy timing, identifying a neutral near-term sentiment and a mid-channel oscillation pattern. It outlines an exceptional 29.1:1 risk-reward setup targeting an 8.4% gain and provides three distinct AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging. The analysis also includes multi-timeframe signal analysis, showing neutral sentiment in the near and long term, with weakness in the mid-term.
How Aptargroup Inc. (ATR) Affects Rotational Strategy Timing
Aptargroup Inc. (ATR) currently exhibits neutral near-term sentiment with a mid-channel oscillation pattern. AI models suggest three trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis indicates an exceptional 29.1:1 risk-reward setup, targeting an 8.4% gain versus 0.3% risk.
17,482 Shares in AptarGroup, Inc. $ATR Acquired by Diversified Management Inc.
Diversified Management Inc. recently acquired 17,482 shares of AptarGroup, Inc. (NYSE:ATR) in the third quarter, valued at approximately $2.12 million. AptarGroup reported strong quarterly results, exceeding analyst estimates with $1.03 billion in revenue and $1.42 EPS, and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $169.00. Institutional investors and hedge funds collectively own a significant 88.52% of the company's stock.
AptarGroup stock gets Deutsche Bank Buy rating at USD 150
Deutsche Bank initiated coverage of AptarGroup (ATR) with a Buy rating and a price target of $150.00, representing a 24.6% upside from its October 7, 2026 price of $120.43. This comes as the company reported a 15% decrease in Q2 adjusted EPS to $1.42, despite a 6.3% rise in revenue to $1.03 billion. The broader analyst consensus, with an average target of $169.00, remains higher than Deutsche Bank's target.
US038336AB93 Bond Yield and Price — BONDSCOM:US038336AB93
This article provides detailed financial information for the AptarGroup, Inc. 4.75% 30-MAR-2031 bond (ISIN US038336AB93), including its credit rating, key terms, and bond issuer details. It outlines the bond's outstanding amount, face value, coupon rate, and maturity date, along with information about AptarGroup, Inc.'s business segments and history. The piece encourages users to sign up for full access to advanced bond data and credit risk comparisons.
Zacks lifts AptarGroup stock estimate from USD 1.45 to USD 1.46
Zacks Research has raised its Q3 2026 earnings per share forecast for AptarGroup from USD 1.45 to USD 1.46. This new estimate is above the lower end of AptarGroup's Q3 guidance. The company reported Q2 2026 revenue of USD 1.03 billion, up 6.30% year-over-year, and earnings per share of USD 1.42.
Aptar Pharma Launches Premia™ Precision, a New Quality Standard for Demanding Injectable Therapies
Aptar Pharma has launched Premia™ Precision, a new quality standard for elastomer components designed for sensitive and high-value injectable therapies. This new standard addresses the increasing complexity and value of injectable drugs like biologics and GLP-1 therapies, focusing on enhanced quality, consistency, and control beyond basic regulatory requirements. Premia™ Precision integrates impact-based quality criteria, risk-driven manufacturing controls, stringent particle management, production data monitoring, and 100% automated vision inspection.
AptarGroup (ATR) Loses 5.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
AptarGroup (ATR) has experienced a 5.9% decline over the past four weeks but appears poised for a trend reversal. The stock is now in oversold territory with an RSI of 29.86, and Wall Street analysts expect better earnings, as indicated by a 0% increase in the consensus EPS estimate over the last 30 days. Additionally, ATR holds a Zacks Rank #2 (Buy), signaling a potential near-term turnaround.